MGC Diagnostics Corporation To Report Third Quarter Fiscal Year 2017 Financial Results On Wednesday, September 6, 2017

Published: Aug 30, 2017

SAINT PAUL, Minn., Aug. 30, 2017 /PRNewswire/ -- MGC Diagnostics Corporation (NasdaqCM: MGCD), a global medical technology company, today scheduled a conference call to discuss its financial results for the third quarter fiscal year 2017, ended July 31, 2017. The call will be at 4:30 p.m. ET on Wednesday, September 6, 2017. The Company will report financial results for the third quarter fiscal year 2017 after the market close on September 6, 2017.

Participants can dial (844) 861-5496 or (412) 317-6578 to access the conference call, or listen via a live Internet webcast on the Company's website at A replay of the conference call will be available by dialing (877) 344-7529 or (412) 317-0088, confirmation code 10111876, through September 13, 2017. A webcast replay of the conference call will be accessible on the Company's website at for 90 days.

About MGC Diagnostics

MGC Diagnostics Corporation (NASDAQ: MGCD) is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its Medical Graphics Corporation and Medisoft SA subsidiaries, develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit


Todd M. Austin           

Joe Dorame, Robert Blum, Joe Diaz

MGC Diagnostics Corporation      

Lytham Partners, LLC

Chief Executive Officer

(602) 889-9700

(651) 484-4874


View original content:

SOURCE MGC Diagnostics Corporation

Back to news